Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101802 | 0.88 | MAPT (0.45) | MAPTTDP1L3MBTL1MAPK1CYP2C9 | |
| SCHEMBL10101770 | 0.85 | MAPT (0.42) | MAPTTDP1L3MBTL1MAPK1CYP2C9 | |
| SCHEMBL10107472 | 0.84 | LMNA (0.44) | MAPTL3MBTL1MAPK1CYP2C9CYP2C19 | |
| SCHEMBL290655 | 0.84 | MAPT (0.41) | MAPTTDP1L3MBTL1MAPK1CYP2C9 | |
| SCHEMBL10101772 | 0.83 | MAPT (0.40) | MAPTTDP1L3MBTL1MAPK1CYP2C9 | |
| SCHEMBL10101766 | 0.81 | PTPN1 (0.43) | MAPTPTPN1TSHRRAB9ANPSR1 | |
| SCHEMBL9285514 | 0.80 | ELANE (0.44) | MAPTTDP1L3MBTL1MAPK1CYP2C9 | |
| SCHEMBL112286 | 0.80 | P4HTM (0.44) | MAPTTDP1L3MBTL1MAPK1CYP2C9 | |
| SCHEMBL10102086 | 0.80 | PTPN1 (0.43) | MAPTPTPN1ALKBH1RAB9ANPSR1 | |
| SCHEMBL10102283 | 0.79 | AOC3 (0.45) | MAPTSMN1; SMN2PTGER1P4HTMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3339303-B9 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3339303-B9 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3339303-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3339303-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10246433-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3339303-A1 | ARYL AND HETEROARYL FUSED LACTAMS | Pfizer Inc (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-3339303-A1 | ARYL AND HETEROARYL FUSED LACTAMS | Pfizer Inc (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2935238-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-2935238-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20170233368-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20150175572-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175572-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-9040515-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040515-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8828988-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| WO-2014097041-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179667-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179667-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8367654-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179667-A1 | ARYL AND HETEROARYL FUSED LACTAMS | CCNY, MLX, NFXL1 | MAPT 4186/4885TDP1 4467/4885L3MBTL1 269/4885 |
| US-20170233368-A1 | ARYL AND HETEROARYL FUSED LACTAMS | CCNY, MLX, NFXL1 | MAPT 4186/4885TDP1 4467/4885L3MBTL1 269/4885 |
| US-20150175572-A1 | ARYL AND HETEROARYL FUSED LACTAMS | CCNY, MLX, NFXL1 | MAPT 4186/4885TDP1 4467/4885L3MBTL1 269/4885 |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TET1, TET3, HDAC8 | MAPT 921/4885TDP1 745/4885L3MBTL1 4756/4885 |
| US-10246433-B2 | Aryl and heteroaryl fused lactams | CCNY, MLX, NFXL1 | MAPT 4186/4885TDP1 4467/4885L3MBTL1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.